RAPT · Insider Trading
RAPT Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by RAPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | Scott Braunstein | Director | A | +4,956 | — |
| 2026-02-02 | Mary Ann Gray | Director | A | +4,956 | — |
| 2026-02-02 | Lori Lyons-Williams | Director | A | +4,956 | — |
| 2026-02-02 | Michael F Giordano | Director | A | +4,956 | — |
| 2026-02-02 | Linda Kozick | Director | A | +4,956 | — |
| 2026-02-02 | Ashley L. Dombkowski | Director | A | +4,956 | — |
| 2025-06-30 | Ashley L. Dombkowski | Director | A | +25,000 deriv. | — |
| 2025-06-24 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | A | +100,000 deriv. | — |
| 2025-06-24 | Rodney KB Young | CHIEF FINANCIAL OFFICER | A | +118,750 deriv. | — |
| 2025-06-24 | Scott Braunstein | Director | A | +25,000 deriv. | — |
| 2025-06-24 | Brian Russell Wong | PRESIDENT AND CEO | A | +637,500 deriv. | — |
| 2025-06-24 | William Ho | CHIEF MEDICAL OFFICER | A | +75,000 deriv. | — |
| 2025-06-02 | Linda Kozick | Director | A | +257,832 deriv. | — |
| 2025-06-02 | Lori Lyons-Williams | Director | A | +257,832 deriv. | — |
| 2025-06-02 | Mary Ann Gray | Director | A | +257,832 deriv. | — |
| 2025-06-02 | Michael F Giordano | Director | A | +257,832 deriv. | — |
| 2025-04-02 | Mary Ann Gray | Director | A | +61,202 deriv. | — |
| 2025-04-02 | Wendye Robbins | Director | A | +49,432 deriv. | — |
| 2025-02-03 | William Ho | CHIEF MEDICAL OFFICER | A | +450,000 deriv. | — |
| 2025-02-03 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | A | +515,000 deriv. | — |
| 2025-02-03 | Brian Russell Wong | PRESIDENT AND CEO | A | +1,746,000 deriv. | — |
| 2025-02-03 | Rodney KB Young | CHIEF FINANCIAL OFFICER | A | +642,000 deriv. | — |
| 2024-12-23 | COLUMN GROUP II, LP | — | J | −14,757,125 | — |
| 2024-12-23 | COLUMN GROUP II, LP | — | J | −29,514,250 | — |
| 2024-11-15 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2024-11-15 | Rodney KB Young | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2024-11-15 | Brian Russell Wong | PRESIDENT AND CEO | MIXED | — | — |
| 2024-11-15 | William Ho | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2024-05-23 | Linda Kozick | Director | A | +36,490 deriv. | — |
| 2024-05-23 | Mary Ann Gray | Director | A | +36,490 deriv. | — |
| 2024-05-23 | Michael F Giordano | Director | A | +36,490 deriv. | — |
| 2024-05-23 | Lori Lyons-Williams | Director | A | +36,490 deriv. | — |
| 2024-05-23 | Wendye Robbins | Director | A | +36,490 deriv. | — |
| 2024-05-23 | William Jl Rieflin | Director | A | +36,490 deriv. | — |
| 2024-04-01 | William Jl Rieflin | Director | A | +11,871 deriv. | — |
| 2024-04-01 | Wendye Robbins | Director | A | +6,925 deriv. | — |
| 2024-04-01 | Mary Ann Gray | Director | A | +8,574 deriv. | — |
| 2024-02-01 | William Ho | CHIEF MEDICAL OFFICER | A | +75,000 deriv. | — |
| 2024-02-01 | Brian Russell Wong | PRESIDENT AND CEO | A | +275,000 deriv. | — |
| 2024-02-01 | Rodney KB Young | CHIEF FINANCIAL OFFICER | A | +90,000 deriv. | — |
| 2024-02-01 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | A | +75,000 deriv. | — |
| 2024-01-08 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | Sell | −898 | −$20.46K |
| 2024-01-02 | Dirk G. Brockstedt | Chief Scientific Officer | M | +8,000 | +$49.44K |
| 2023-12-22 | William Ho | Chief Medical Officer | Sell | −2,500 | −$54.20K |
| 2023-11-29 | William Ho | Chief Medical Officer | Sell | −1,500 | −$20.58K |
| 2023-10-04 | William Ho | Chief Medical Officer | Sell | −2,500 | −$39.42K |
| 2023-08-22 | William Ho | Chief Medical Officer | Sell | −2,500 | −$47.30K |
| 2023-08-03 | William Ho | Chief Medical Officer | M | +460 | +$5.52K |
| 2023-06-27 | William Ho | Chief Medical Officer | M | +920 | +$11.04K |
| 2023-05-25 | Linda Kozick | Director | A | +12,940 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| COLUMN GROUP II, LP | 10%+ Owner | 160,783 | $9.33M |
| Brian Russell Wong | PRESIDENT AND CEO | 60,500 | $3.51M |
| Mary Ann Gray | Director | 4,956 | $287.50K |
| Ashley L. Dombkowski | Director | 4,956 | $287.50K |
| Scott Braunstein | Director | 4,956 | $287.50K |
| Lori Lyons-Williams | Director | 4,956 | $287.50K |
| Michael F Giordano | Director | 4,956 | $287.50K |
| Linda Kozick | Director | 4,956 | $287.50K |
| Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | 3,478 | $201.76K |
| Wendye Robbins | Director | 2,550 | $147.93K |
| William Ho | CHIEF MEDICAL OFFICER | 1,878 | $108.94K |
| Rodney KB Young | CHIEF FINANCIAL OFFICER | 1,260 | $73.09K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RAPT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.